Specialty Pharmacy

Mark Zitter, CEO at Zitter Health Insights, explains how the growth of Accountable Care Organizations may impact specialty drug management in the near future.

The Center for Pharmacy Practice Accreditation (CPPA) recently announced the development of an accreditation program for specialty pharmacy practices.

Specialty Pharmacy Times spoke with Eric Sredzinski, PharmD, AAHIVE, vice president, clinical affairs at Avella, to find out more about their adherence initiative with Novartis and how the GlowCap can help optimize patient health.

Secukinumab is the first therapy that selectively targets IL-17A in psoriasis to complete a Phase III trial.

Employers and health plans can begin to take control of these specialty drug costs by following 7 steps outlined in a new report released today by Prime.

Negative findings were reported for both clinical and imaging measures in a Phase II randomized trial of riluzole in comparison to placebo in patients with very early multiple sclerosis (MS).

Amid legislative shutdown, some drug review operations tied to residual user fees continue, but all nonemergency activities related to biosimilars have been suspended indefinitely.

A recent study compared the annual cost per treated patient for a health plan for patients taking etanercept, adalimumab, or infliximab.

Bill Sullivan of the Specialty Pharmacy Association of America describes the growth of the specialty pharmacy industry and the factors that prompted the formation of SPAARx.

Today, more than 30 pharmacy organizations across the globe will go on Twitter for American Pharmacists Month.

Rheumatologists in Austria and The Netherlands have proposed a reclassification of synthetic disease-modifying antirheumatic drugs (DMARDs) into targeted synthetic DMARDs and conventional synthetic DMARDs.

The 2014 10th Annual Specialty Pharmacy Summit & Expo, Hosted by Armada Health Care, is pleased to announce that individual attendee registration is now open for the conference.

Avella Specialty Pharmacy has been chosen by Navitus Health Solutions LLC to provide Synagis to its managed Medicaid members in Texas and Colorado.

Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.

Investigators in the Czech Republic have found an association between soft tissue lesions and diminished survival in patients with multiple myeloma.

Managed Health Care Associates, Inc (MHA) is pleased to announce that the latest release of RxPertise Consulting Software.

The Generic Pharmaceutical Association petition recommends that the FDA use the active ingredient in a reference biologic when naming a biosimilar product.

The FDA has added a new black box warning to 2 drugs, rituximab (Rituxan) and ofatumumab (Arzerra) for the potential of either drug to cause reactivation of hepatitis B virus (HBV).

Leaders from the Senate and House committees overseeing health policy announced that they have reached an agreement on legislation to help ensure the safety of compounded drugs and our nation's pharmaceutical supply chain.

Manufacturers often select their specialty drug distribution strategy based on the level of REMS reporting required by the FDA. What are some things keeping specialty pharmacies and manufacturers from collecting the data they truly want?

Michael Einodshofer of Walgreens identifies the various charges that can be included in the total cost of an infusion in a hospital setting.

In response to the lobbying efforts of SPAARx and other industry organizations over the past months, the Department of Health and Human Services (HHS) provided revised guidance on remuneration for refill reminders and other similar communications.

Health care reform will undoubtedly change the way specialty drugs are managed within the distribution supply chain, and specialty pharmacy providers may soon be competing with hospitals for patient share.

Between 21% and 28% of patients taking an oral therapy for hepatocellular carcinoma (HCC) were nonadherent to treatment. Certain groups of patients may benefit from counseling services that promote improved adherence.

A study compared historical and contemporary multiple sclerosis cases to determine how first-generation disease-modifying drugs affected disease progression.

Seniors have medication needs that cannot sufficiently be met by mail-service pharmacy, a recent study in the Journal of Managed Care Pharmacy suggests.

The Patients' Access to Treatments Act of 2013 proposes limits on patients' costs for specialty drugs.

Data from a national survey on community health in racial and ethnic groups suggest specific socioeconomic barriers to hepatitis C virus detection and therapy.